The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs

We investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L1) expression in lung cancer and their potential in distinguishing between different histological subtypes of non-small cell lung cancers (NSCLCs). Thirty-five patients diagnosed with stage III NSCLC...

Full description

Bibliographic Details
Main Authors: Chandra Bortolotto, Gaia Messana, Antonio Lo Tito, Giulia Maria Stella, Alessandra Pinto, Chiara Podrecca, Riccardo Bellazzi, Alessia Gerbasi, Francesco Agustoni, Fei Han, Marcel Dominik Nickel, Domenico Zacà, Andrea Riccardo Filippi, Olivia Maria Bottinelli, Lorenzo Preda
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/15/12/3252
Description
Summary:We investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L1) expression in lung cancer and their potential in distinguishing between different histological subtypes of non-small cell lung cancers (NSCLCs). Thirty-five patients diagnosed with stage III NSCLC from April 2021 to December 2022 were included. Conventional MRI sequences were acquired with a 1.5 T system. Mean T1 and T2 mapping values were computed for six manually traced ROIs on different areas of the tumor. Data were analyzed through RStudio. Correlation between T1/T2 mapping values and PD-L1 expression was studied with a Wilcoxon–Mann–Whitney test. A Kruskal–Wallis test with a post-hoc Dunn test was used to study the correlation between T1/T2 mapping values and the histological subtypes: squamocellular carcinoma (SCC), adenocarcinoma (ADK), and poorly differentiated NSCLC (PD). There was no statistically significant correlation between T1/T2 mapping values and PD-L1 expression in NSCLC. We found statistically significant differences in T1 mapping values between ADK and SCC for the periphery ROI (<i>p</i>-value 0.004), the core ROI (<i>p</i>-value 0.01), and the whole tumor ROI (<i>p</i>-value 0.02). No differences were found concerning the PD NSCLCs.
ISSN:2072-6694